PharmiWeb2m
Gerresheimer AG: Adjustment of growth guidance for 2024 and 2025
Düsseldorf, September 30, 2024 – Gerresheimer AG (ISIN: DE000A0LD6E6) is adjusting its growth guidance for 2024 and 2025 due to the significantly slower than expected market recovery 2024 and lower ...
PharmiWeb9m
Revolutionizing Med Spa Excellence: Academy of Aesthetics Offers Top-Tier Medical Director Services and Private Training for Injectors
BC, CANS, announces the launch of its Medical Director services and Private Training programs for aesthetic injectors. With over a decade of industry experience, Megan Davies is setting a new standard ...
PharmiWeb56m
Hypha Labs, Inc. Reveals First Functional Mushroom Ingredient Array for Home and Commercial Production
First Generation ‘MicroPearls Pro™'and "MicroPearls ProX™" Will Support Largest Mushroom Ingredient CategoriesLAS VEGAS, NV / ACCESSWIRE / September 30, 2024 / Hypha Labs, Inc. (OTCQB:FUNI), a pioneer ...
PharmiWeb1h
Axis Integrated Mental Health Recognized as Top Startup for Advancing Collaborative Mental Health Care
Top Startup Award Marks a Year of Milestones for Colorado's Leading Mental Health InnovatorWESTMINSTER, CO / ACCESSWIRE / ...
PharmiWeb1h
Study Indicates Significant Radiation Reduction for Breast Cancer Patients
Lumpectomy Patients Received VeraForm® Marker and APBI Therapy for Breast Cancer TreatmentSAN FRANCISCO, CA / ACCESSWIRE / September 30, 2024 / A recent study accepted by the American Society of ...
PharmiWeb2h
Modular Medical to Present at the Lytham Partners Fall 2024 Investor Conference on October 1
SAN DIEGO, CA / ACCESSWIRE / September 30, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump ...
PharmiWeb3h
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
Business combination to form a best-in-class, transformative oral biologics company - Synergies between Tharimmune's clinical-stage assets and Intract's delivery platform to drive pipeline growth - ...
PharmiWeb3h
Moderna Announces First Participant Dosed in Pivotal Phase 3 Trial of Investigational mRNA Norovirus Vaccine, mRNA-1403
CAMBRIDGE, MA / ACCESSWIRE / September 30, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first participant in the U.S. has been dosed in the Nova 301 Trial, a pivotal Phase 3 randomized ...
PharmiWeb4h
Medacta Hosts Inaugural Capital Markets Day, Showcasing Responsible Innovation and Effective Growth Strategy
MiscellaneousMedacta Hosts Inaugural Capital Markets Day, Showcasing Responsible Innovation and Effective Growth Strategy 30.09.2024 / 12:00 CET/CESTMEDIA RELEASEMedacta Hosts Inaugural Capital ...
PharmiWeb5h
Boehringer Ingelheim partners with NCD Alliance to target Non-Communicable Diseases in underserved communities
Boehringer Ingelheim has entered a partnership with the NCD Alliance, a network dedicated to shaping a world in which ...
PharmiWeb8h
Genflow Biosciences PLC Announces Half-year Report
LONDON, UNITED KINGDOM / ACCESSWIRE / September 30, 2024 / Genflow (LSE:GENF) is pleased to announce its half year results for the six-month period ended 30 June 2024.Chairman's StatementIt is with ...
PharmiWeb8h
Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
Regulatory Approval/Market LaunchFormycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz) 30.09.2024 / 07:30 CET/CESTThe issuer is solely responsible for the content of ...